Longeveron (LGVN) Price & Analysis

Compare

592 Followers

LGVN Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.63 - $2.48

Previous CloseN/A

Volume215.49K

Average Volume (3M)427.41K

Market Cap

$19.53M

Enterprise Value$10.32M

Total Cash (Recent Filing)$10.33M

Total Debt (Recent Filing)$639.00K

Price to Earnings (P/E)―

Beta1.43

Next Earnings

Nov 07, 2025

EPS Estimate

-0.26

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.33

Shares Outstanding19,576,923

10 Day Avg. Volume502,279

30 Day Avg. Volume427,409

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.53

Enterprise Value/Revenue4.98

Enterprise Value/Gross Profit6.32

Enterprise Value/Ebitda-0.55

Forecast

1Y Price Target

$3.50

Price Target Upside297.73% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Funding And Financial SupportGrant funding from the National Institute of Health offsets the expenses of the study, providing financial support for the research.

Partnership OpportunitiesThe company is exploring partnerships for laromestrocel in Alzheimer's disease, following positive results from a Type B meeting that supported a pivotal study.

Research And DevelopmentLongeveron is making progress in its study of laromestrocel in HLHS, with topline data expected in 2026, which could support registration and potential approval by 2027.

Bears Say

Stock DilutionThe company's recent equity financing has led to dilution, which has contributed to a lowered 12-month price target from $6.00 to $4.00.

Longeveron News

Longeveron Appoints Dr. George Paletta to Board

Longeveron ( ($LGVN) ) just unveiled an announcement. On October 1, 2025, Longeveron Inc. announced the appointment of...

9d ago

LGVN

Longeveron Faces Nasdaq Delisting Notice for Stock Price

An update from Longeveron ( ($LGVN) ) is now available. On September 22, 2025, Longeveron Inc. received a...

14d ago

LGVN

Longeveron Announces Leadership Changes Amidst CEO Departure

Longeveron ( ($LGVN) ) has issued an announcement. On August 27, 2025, Longeveron Inc. announced a leadership change...

1M ago

LGVN

Longeveron CEO Wa’el Hashad to step down

Longeveron (LGVN) announced leadership updates. The company’s board of directors has appointed Than Powell as interim CEO, effective...

1M ago

LGVN

Longeveron Inc. Earnings Call: Progress Amid Challenges

Longeveron Inc. (($LGVN)) has held its Q2 earnings call. Read on for the main highlights of the call....

1M ago

LGVN

Longeveron: Buy Rating Backed by Promising Clinical Developments and Strategic Financial Outlook

Maxim Group analyst Michael Okunewitch has maintained their bullish stance on LGVN stock, giving a Buy rating yesterday....

2M ago

LGVN

Longeveron price target lowered to $3 from $10 at Roth Capital

Roth Capital lowered the firm’s price target on Longeveron (LGVN) to $3 from $10 and keeps a Buy...

2M ago

LGVN

Longeveron Inc. Faces Regulatory and Manufacturing Challenges Threatening Financial Stability

Longeveron Inc. (LGVN) has disclosed a new risk, in the Manufacturing category. Longeveron Inc. faces significant business risks...

2M ago

LGVN

Longeveron Inc. Reports Q2 2025 Financial Results

Longeveron Inc. ( ($LGVN) ) has released its Q2 earnings. Here is a breakdown of the information Longeveron...

2M ago

LGVN

Longeveron Closes $5 Million Public Stock Offering

Longeveron ( ($LGVN) ) has issued an announcement. On August 8, 2025, Longeveron announced the pricing of a...

2M ago

LGVN

LGVN Earnings this Week: How Will it Perform?

Longeveron Inc. (LGVN) is scheduled to report 2nd quarter earnings on 08/13/2025, after the market closes. Regarding Q2...

2M ago

LGVN

Longeveron announces $17.5M Class A common stock offering

Longeveron (LGVN) announced the pricing of a public offering of 5.88M of the company’s Class A common stock,...

2M ago

LGVN

Longeveron files to sell 3.85M shares of Class A common stock

16:05 EDT Longeveron (LGVN) files to sell 3.85M shares of Class A common stock Published first on TheFly...

2M ago

LGVN

Longeveron licenses patent for stem cell technology from University of Miami

Longeveron (LGVN) has licensed an issued US patent for a stem cell technology from the University of Miami....

3M ago

LGVN

LGVN FAQ

What was Longeveron Inc.’s price range in the past 12 months?

Longeveron Inc. lowest stock price was $0.63 and its highest was $2.48 in the past 12 months.

What is Longeveron Inc.’s market cap?

Longeveron Inc.’s market cap is $19.53M.

When is Longeveron Inc.’s upcoming earnings report date?

Longeveron Inc.’s upcoming earnings report date is Nov 07, 2025 which is in 28 days.

How were Longeveron Inc.’s earnings last quarter?

Longeveron Inc. released its earnings results on Aug 13, 2025. The company reported -$0.33 earnings per share for the quarter, beating the consensus estimate of -$0.35 by $0.02.

Is Longeveron Inc. overvalued?

According to Wall Street analysts Longeveron Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Longeveron Inc. pay dividends?

Longeveron Inc. does not currently pay dividends.

What is Longeveron Inc.’s EPS estimate?

Longeveron Inc.’s EPS estimate is -0.26.

How many shares outstanding does Longeveron Inc. have?

Longeveron Inc. has 19,576,923 shares outstanding.

What happened to Longeveron Inc.’s price movement after its last earnings report?

Longeveron Inc. reported an EPS of -$0.33 in its last earnings report, beating expectations of -$0.35. Following the earnings report the stock price went down -11.628%.

Which hedge fund is a major shareholder of Longeveron Inc.?

Currently, no hedge funds are holding shares in LGVN

Company Description

Longeveron Inc.

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.

Longeveron (LGVN) Earnings & Revenues

Historic Earnings Reports

LGVN Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The call highlighted significant progress in clinical trials and pipeline expansion, alongside strategic moves in manufacturing readiness and financial planning. However, these were tempered by declines in revenue and increased expenses, alongside some regulatory and financial uncertainties.View all LGVN earnings summaries

LGVN Stock 12 Month Forecast

Average Price Target

$3.50

▲(297.73% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","5":"$5","-1":"-$1","0.5":"$0.5","3.5":"$3.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$4.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$3.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$3.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.5,2,3.5,5],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Mar<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.74,0.9907692307692307,1.2415384615384615,1.4923076923076923,1.743076923076923,1.9938461538461538,2.2446153846153845,2.495384615384615,2.746153846153846,2.9969230769230766,3.247692307692308,3.4984615384615383,3.7492307692307687,{"y":4,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.74,0.9523076923076923,1.1646153846153846,1.376923076923077,1.589230769230769,1.8015384615384613,2.0138461538461536,2.2261538461538457,2.4384615384615382,2.6507692307692308,2.863076923076923,3.075384615384615,3.287692307692307,{"y":3.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.74,0.9138461538461538,1.0876923076923077,1.2615384615384615,1.4353846153846153,1.609230769230769,1.783076923076923,1.9569230769230768,2.1307692307692303,2.304615384615384,2.478461538461538,2.652307692307692,2.8261538461538462,{"y":3,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.57,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.04,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.04,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.03,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.06,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.73,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.52,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.56,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.25,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.28,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.64,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.82,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.74,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >